25 results about "Hiv infected" patented technology

The invention discloses an application of CD4 + CD8 + double-positive T cells in improvement of poor immune reconstitution of HIV (human immunodeficiency virus) infected patients, and relates to the technical field of biological pharmacy, in particular to the application of preparation of the CD4 + CD8 + double-positive T cells in the poor immune reconstitution of the HIV infected patients. The number of peripheral blood CD4 + T cells of HIV infected patients is increased, the immune system of the patients is improved, and the probability of possible opportunity infection and other related diseases of the patients is reduced, so that the morbidity and mortality of the patients are reduced.

The invention belongs to the technical field of medical information, and particularly relates to a newly diagnosed HIV infected person antiviral treatment intelligent decision support system which comprises a multi-source data integration module, a medicine knowledge module, an individualized decision support module, an interactive output module, a knowledge optimization module and a safety and privacy protection module. The system replaces doctors to query and integrate patient data across multiple systems, clinical time is saved, key information omission is avoided, comprehensive data support is provided for treatment decisions, experience decisions are converted into systematic analysis and graded risk prompts are generated by means of an individualized decision support module, scheme deviation is effectively reduced, the medication risk is reduced, and the treatment efficiency is improved. The method assists the basic level in improving the treatment normalization, allows doctors to input new experience and new achievements summarized in practice into the system after double-blind auditing, and provides continuously iterative knowledge support for the scientificity of the antiviral treatment decision of the newly diagnosed HIV infected person.

Engineered TCR molecules specific to retroviral peptide / HLA complexes guide direct killing and / or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (Vα) domain, a TCR variable beta domain (Vβ) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.

The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and / or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

The invention relates to an anti-HIV broad-spectrum neutralizing antibody with an ADCC effect and application of the anti-HIV broad-spectrum neutralizing antibody in treatment and / or prevention of HIV infected diseases. The antibody FD22 disclosed by the invention shows broad-spectrum and strong neutralizing capacity on different subtype HIV-1 pseudoviruses which are prevalent globally, and particularly shows excellent neutralizing activity on HIV-1AE and BC subtype strains which are prevalent widely in China. The antibody FD22 is an effective supplement for the existing HIV neutralizing antibody drug library, and can provide more comprehensive prevention and treatment choices for Chinese epidemic strains. Meanwhile, the antibody FD22 can promote expression of NK cell activating factors, activate NK cells and improve the degranulation effect of the NK cells, so that the killing effect of immune cells such as the NK cells on HIV infected cells is enhanced, and the potential of treating HIV infection is shown.

The invention discloses application of brusatrolactone A in preparation of a medicine for treating HIV infectious diseases, and belongs to the technical field of biological medicine. The invention provides an application of gall gall lactone A in preparation of a medicine for treating human immunodeficiency virus infectious diseases. The invention also relates to a pharmaceutical composition for treating the HIV infection disease, and the pharmaceutical composition comprises the brusatrolactone A and pharmaceutically acceptable auxiliary materials. A cell model experiment proves that the brusatrolactone A has a remarkable effect on inhibiting HIV (human immunodeficiency virus) from invading cells and inhibiting the replication of the HIV in host cells. The medicament not only expands the medicament selection of HIV infection, but also further expands the application range of the brusatrolactone A.

The invention belongs to the field of medicines, and relates to an application of a small molecule drug in anti-HIV-1 latency. The invention provides an application of a micromolecule PTR4165 in preparation of an anti-HIV-1 latency drug. The anti-HIV-1 latency drug is a drug for promoting the transcription activation of a previrus in an HIV infected cell. The micromolecule PTR4165 can be combined with an HIV potential activator to be used as a pharmaceutical composition for promoting the transcription activation of a pre-virus in an HIV infected cell; the HIV potential activator comprises a histone deacetylase inhibitor SAHA, a BET inhibitor JQ1, a PKC agonist and a DNA methylation inhibitor 5-aza. The PTR4165 provided by the invention has a transcriptional activation effect on latent HIV in HIV infected cells no matter the PTR4165 is independently used or combined with a known activator, and can assist in deeper removal of HIV viruses.

The invention discloses a cord blood separation and pathogen detection integrated system in the technical field of blood detection. The cord blood separation and pathogen detection integrated system comprises an information acquisition module, a data processing module, a separation module and a pathogen confirmation module, the information acquisition module is used for acquiring image information of umbilical cord blood cells; the data processing module analyzes the acquired image information through a trained deep learning model, judges whether the sample is HIV infection, HBV infection or non-infection, marks the sample which is judged to be HIV infection and HBV infection, and transmits the marked sample to the pathogen confirmation module; the separation module is used for centrifuging the umbilical cord blood sample and extracting stem cells; the pathogen confirmation module comprises a nucleic acid detection unit and an antigen-antibody detection unit, and the nucleic acid detection unit is used for automatically extracting cell nucleic acid and confirming whether the samples are infected or not according to the HIV infected and HBV infected samples marked by the data processing module; the antigen-antibody unit and a nucleic acid detection result are mutually verified through a chemical judge immunoassay method.

The purpose of the present invention is to provide a method for detecting whether a subject is infected with AIDS virus (HIV) or is in a latent HIV infection state, or whether the subject is suspected of being infected with HIV or being in a latent HIV infection state.　The present invention provides a method for determining whether a mammalian subject is infected with HIV or is in a latent HIV infection state, or whether the mammalian subject is suspected of being infected with HIV or being in a latent HIV infection state, the method involving: a step for detecting the amount of 3-methylcytidine (m3C) in a sample derived from the subject; and a step for providing information on the detected amount for the determination.

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

The invention belongs to the technical field of traditional Chinese medicines, and discloses an anti-aging traditional Chinese medicine composition as well as a preparation method and application thereof. The composition is prepared from 12-24 parts of fructus lycii, 12-24 parts of raspberry, 12-15 parts of emblic leafflower fruit, 24 parts of rhizoma polygonati, 12-24 parts of pulp of dogwood fruit, 6 parts of folium mori and 9 parts of rhodiola rosea. The traditional Chinese medicine composition is guided by the theory of traditional Chinese pharmacology, follows the anti-aging core of reinforcing kidney, strengthening spleen and stomach and regulating liver pivot, is combined with clinical practice to screen traditional Chinese medicines with anti-oxidation and anti-inflammatory effects, and can tonify deficiency and strengthen body resistance. Clinical research proves that after the composition intervenes the HIV infected person for 3 months, the composition can significantly reduce the early apoptosis rate of peripheral T cells, improve the Ki67 proliferation index of CD4 + T cells and CD8 + T cells, relieve immune depletion, have no abnormal blood routine and liver and kidney functions, can improve clinical symptoms such as insomnia and weakness, improve the energy level of the body, and provide a safe and effective scheme for premature senility intervention of the HIV infected person.

The invention relates to the technical field of biomedicine, in particular to application of a gene marker for risk assessment of active tuberculosis of an HIV infected person. According to the application of the provided quantitative detection reagent of the gene marker in preparation of a product for evaluating the risk of the HIV infected person suffering from the active tuberculosis, the gene marker shown as Seq.No1-6 comprises one or more of BEX5, CEL, DUSP14, EIF3I, PPFIA4 and TSEN2, and the gene marker shown as Seq.No1-6 comprises one or more of BEX5, CEL, DUSP14, EIF3I, PPFIA4 and TSEN2. According to the application, the problem of identifying active tuberculosis high-risk groups in HIV infected persons is solved from the gene level, the disease progress trend can be captured earlier and more accurately from the gene level, and a foundation is laid for targeted implementation of tuberculosis preventive treatment.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.

The invention discloses application of ipecine in preparation of a medicine for treating HIV infectious diseases, and belongs to the technical field of biological medicines. The invention provides an application of ipecine in preparation of a medicine for treating human immunodeficiency virus infectious diseases. The invention also relates to a pharmaceutical composition for treating the HIV infection diseases, and the pharmaceutical composition comprises ipecine and pharmaceutically acceptable auxiliary materials. A cell model experiment proves that the ipecine has a remarkable effect on inhibiting HIV (Human Immunodeficiency Virus) from invading cells and inhibiting the replication of the HIV in host cells. The drug not only expands the drug selection of HIV infection, but also further expands the application range of the ipecine.

The present invention relates to bispecific antibodies against CD3 and Human Immunodeficiency Virus (HIV) Env, to treat HIV infection.

The invention belongs to the technical field of single-chain antibodies, and provides a human anti-cytomegalovirus single-chain neutralizing antibody scFv-26 and application thereof. The human anti-cytomegalovirus single-chain neutralizing antibody scFv-26 with an amino acid sequence as shown in SEQ ID NO.1 is obtained by constructing a phage display library and carrying out solubilization expression and purification on the antibody. As a novel biological treatment means, the human anti-cytomegalovirus single-chain neutralizing antibody shows a wide application prospect in a plurality of medical fields. Firstly, the compound plays a key role in immunosuppressive people, such as organ transplantation patients, HIV infected people, cancer chemotherapy patients and the like; secondly, the method plays an important role in prevention and control of maternal and infant transmission, can provide early treatment choices for congenital CMV infected infants, and reduces sequelae risks. The immunogenicity is remarkably reduced by the humanized design, and the single-chain structure endows high stability and tissue penetrating power, so that the single-chain structure can be easily developed into a long-acting preparation or an inhalation administration form.

The invention belongs to the field of biomedicine, and particularly relates to biomarkers for diagnosis or auxiliary diagnosis of HIV (Human Immunodeficiency Virus) combined hyperlipemia and application of the biomarkers, and the biomarkers are PLIN5 and GPX3. Differential expression genes of HIV combined with hyperlipemia are screened through transcriptome sequencing, the diagnosis efficiency of the differential expression genes is verified in multiple layers through an internal queue, an external database and a clinical sample, and finally it is determined that PLIN5 and GPX3 can be used for diagnosing or assisting in diagnosing whether hyperlipemia exists in an HIV infected population or not. The method provides guidance for early intervention of hyperlipemia in HIV infected populations, and has a wide clinical application prospect.

The present disclosure is directed to N-oxide derivatives of Formula I (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

The invention belongs to the field of medical research, and particularly relates to a method, system and device for evaluating HIV antiviral therapy compliance and a storage medium. The method comprises the following steps: acquiring index data for reflecting ART compliance of an HIV infected person, wherein the index data comprises a nursing retention state, a drug holding rate and a CD4 cell count; constructing a group trajectory model GBTM, and identifying trajectory subgroups of different antiviral treatment compliance in the HIV infected person based on the index data; utilizing a Logistic regression model to evaluate the influence of the demology and ART variable level of different HIV infected persons on the affiliation probability of each trajectory subgroup; utilizing a Cox proportional risk model to evaluate the association between each track subgroup and all-factor death, AIDS death and non-AIDS death; and finally, constructing a dynamic prediction model based on the nursing retention, the drug coverage rate and the CD4 cell counting data by using the combined model, so as to realize real-time early warning of the death risk.

The present disclosure is directed to pyridinone derivatives of Formula Iand their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

The application of homoharringtonine in the preparation of drugs for treating HIV-infected diseases belongs to the field of biomedical technology. This invention provides the application of homoharringtonine in the preparation of drugs for treating HIV-infected diseases; and a pharmaceutical composition for treating HIV infection, said composition comprising homoharringtonine and pharmaceutically acceptable excipients. This invention demonstrates through cell model experiments that homoharringtonine has a significant effect on inhibiting HIV invasion of cells and inhibiting HIV replication within host cells. This drug not only expands the selection of drugs for HIV infection but also further broadens the application scope of homoharringtonine.

The invention provides a marker composition, a kit and a prediction and evaluation method for evaluating the risk of immune reconstitution insufficiency of an HIV (Human Immunodeficiency Virus) infected person, and the marker composition, the kit and the prediction and evaluation method are used for predicting and evaluating the risk of immune reconstitution insufficiency of the HIV infected person by adopting the combination of three markers of an interferon gamma-induced mononuclear cell chemokine (MIG), a nerve growth factor (NGF) and granzyme B (GZMB). Effective evaluation and auxiliary diagnosis of the risk of incomplete immune reconstitution (INR) of an HIV infected person under long-term anti-retrovirus treatment are realized, the prediction sensitivity, specificity and stability are improved, and a basis is provided for clinical early intervention and individualized management.

The application belongs to the technical field of biological medicine, and specifically discloses application of FKBP5 and hsa-miR-320a-3p in diagnosis of tuberculosis in HIV infected population. It is found that FKBP5 and hsa-miR-320a-3p can be used as biomarkers for diagnosing tuberculosis in HIV / AIDS population, and have the advantages of high sensitivity, high specificity, fast detection speed and the like, and are suitable for screening of tuberculosis in HIV / AIDS population. The application provides a new biomarker and detection method for diagnosis of HIV combined with mycobacterium tuberculosis infection, and is beneficial to early diagnosis and early treatment of HIV combined with mycobacterium tuberculosis infection, prolongs the life of patients, and improves the life quality of patients.

The present application belongs to the field of biomedicine, and particularly relates to biomarkers for diagnosing or assisting in diagnosing HIV combined with hyperlipidemia and application thereof, wherein the biomarkers are PLIN5 and GPX3. The present application screens differential expression genes of HIV combined with hyperlipidemia through transcriptome sequencing, verifies the diagnostic efficiency thereof through internal queue, external database and clinical sample multi-level verification, and finally determines that PLIN5 and GPX3 can be used for diagnosing or assisting in diagnosing whether hyperlipidemia exists in HIV infected population, provides guidance for early intervention of hyperlipidemia in HIV infected population, and has broad clinical application prospect.